Skip to main content
. 2017 Apr 24;61(5):e01867-16. doi: 10.1128/AAC.01867-16

FIG 4.

FIG 4

Within-host selection of atovaquone-resistant mutations with a therapeutic high dose (top) or a subtherapeutic low dose (bottom) of atovaquone. Mutants with lesions in the Qo2 domain, associated with a higher degree of resistance (red circles), or in the Qo1 domain, associated with lower degree of resistance (blue circles), were selected independently.